← All trials
NCT06008106
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2023
- Primary completion
- Sep 22, 2027
- Completion date
- Sep 22, 2027
- First posted
- Aug 23, 2023
- Last posted
- Aug 23, 2023
- Enrollment
- 165
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Kechow PharmaLead sponsor
- Kechow PharmaStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.